

## 2016 European Guidelines on CVD prevention in clinical practice - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Agewall Stefan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Thermo Fischer Scientific : Cardiac markers (2014-2015)</li> <li>- Astra Zeneca : Platelet inhibition (2014-2015)</li> <li>- Vifor International : Heart failure (2015)</li> </ul>
Albus Christian	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Hospital "Porz am Rhein gGmbH", Cologne : Adherence in CHD (2014)</li> <li>- Servier : Anxiety and Depression in CHD (2014)</li> <li>- German Diabetes Society : Behaviour change in Diabetes mellitus (2014)</li> <li>- Self Help Group for patients with Pulmonary Hypertension : Coping with illness (2014)</li> <li>- German Cardiac Society : Psychocardiology (2014)</li> <li>- Elsevier : Psychocardiology (2014-2015)</li> <li>- Deutscher Ärzteverlag : Psychocardiology (2014-2015)</li> <li>- Schattauer Verlag : Psychotherapy (2014-2015)</li> <li>- Sanofi Aventis : Adherence in Diabetes mellitus (2015)</li> <li>- Helios Klinikum, Wuppertal : Anxiety and Depression in CHD (2015)</li> <li>- Hospital "Rhein Klinik", Bad Honnef : Psychosocial aspects in CHD (2015)</li> <li>- LVR Klinikum Essen : Psychosocial aspects in CVD (2015)</li> <li>- PsychotherapeutenForum Aachen eV : Psychosocial aspects in CVD (2015)</li> <li>- Deutsche Hypertonie Liga : Psychosocial aspects in Hypertension (2015)</li> <li>- Sportärztebund Nordrhein eV : Psychosocial risk factors in CAD (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- German Research Foundation : Psychotherapy in cardiac patients with depression (2014-2015)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- German Research Foundation : Psychotherapy in cardiac patients with depression (2014-2015)</li> </ul>

## 2016 European Guidelines on CVD prevention in clinical practice - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Binno Simone	Nothing to be declared (2014-2015)
Brotons Carlos	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Brilinta (2014)</li> <li>- Pfizer : Apixaban (2014-2015)</li> <li>- Bayer : Aspirin (2014-2015)</li> <li>- Lundbeck : Selincro (2014-2015)</li> <li>- MSD-Spain : lipids (2015)</li> </ul>
Catapano Alberico	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Amgen : Cardiovascular (2014)</li> <li>- Astra Zeneca : Cardiovascular (2014)</li> <li>- Pfizer : Cardiovascular (2014)</li> <li>- Sanofi Aventis : Cardiovascular (2014)</li> <li>- Esteve : Cardiovascular (2014)</li> <li>- Merck Sharp &amp; Dohme : Cardiovascular (2014-2015)</li> <li>- Kowa : Cardiovascular (2014-2015)</li> <li>- Recordati International : Cardiovascular (2015)</li> <li>- Aatra Zeneca : Cardiovascular (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Amgen : Cardiovascular (2015)</li> <li>- Pfizer : Cardiovascular (2015)</li> <li>- Sanofi Aventis : Cardiovascular (2015)</li> <li>- Aegerion : Cardiovascular (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Pfizer : Cardiovascular (2015)</li> </ul>

## 2016 European Guidelines on CVD prevention in clinical practice - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Catapano Alberico	<ul style="list-style-type: none"> <li>- Sanofi Aventis : Cardiovascular (2015)</li> <li>- Merck Sharp &amp; Dohme : Cardiovascular (2015)</li> </ul>
Cooney Marie Therese	Nothing to be declared (2014-2015)
Corra Ugo	Nothing to be declared (2014-2015)
Cosyns Bernard	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Pfizer : Apixaban (2014)</li> <li>- Bristol Myers Squibb : Apixaban (2014)</li> <li>- Therabel : molsidomine (2014)</li> <li>- Zambon : Zanicombo (2014)</li> <li>- St Jude Medical : Trifecta valve (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Dabigatran (2014-2015)</li> <li>- Johnson &amp; Johnson : MMR nanobodies (2014-2015)</li> <li>- St Jude Medical : pacing (2014-2015)</li> </ul>
Deaton M Christi	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : none (2014-2015)</li> <li>- Boehringer-Ingelheim : none (2014-2015)</li> <li>- Daiichi Sankyo : none (2014-2015)</li> <li>- Sanofi Aventis : none (2014-2015)</li> </ul>
Graham Ian Maklim	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Advisory Board (2014-2015)</li> <li>- Merck Sharp &amp; Dohme : CVD risk factor audit (2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : CVD risk factor audit (2014)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- World Health Organisation : Co-Chair of Expert Advisory Group developing a new CVD risk estimation system (2015)</li> </ul>

## 2016 European Guidelines on CVD prevention in clinical practice - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Hall Michael S	Nothing to be declared (2014-2015)
Hobbs Richard	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : AF (2015)</li> <li>- Boehringer-Ingelheim : Af (2015)</li> <li>- Pfizer : Lipids/Anticoag (2015)</li> </ul> <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> <li>- Amgen Inc : CV risk and lipids (2014)</li> <li>- Boehringer-Ingelheim : stroke (2014)</li> <li>- Pfizer : stroke (2014)</li> <li>- Bayer Healthcare : stroke (2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : AF screening (2014)</li> <li>- Pfizer : ;lipids (2015)</li> </ul>
Hoes Arno	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Various : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2014)</li> <li>- Zorg binnen Bereik : Member of project team of Zorg Binnen Bereik, a Dutch Achmea (health insurance company) and Philips sponsored research program to test patient e-health platforms in patients with chronic disease (heart failure, COPD and diabetes) (2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addi : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2014)</li> </ul>

## 2016 European Guidelines on CVD prevention in clinical practice - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Hoes Arno	- I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2015)
Lochen Maja-Lisa	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pfizer : no kr 4000 for a lecture on snuff (snus) and health effects (2014) C - Receipt of royalties for intellectual property. - Royalties for 3 medicine books from Gyldendal Akademisk forlag : Medicine books (2015)
Loellgen Herbert	Nothing to be declared (2014-2015)
Marques-Vidal Pedro	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Swiss national fund : PhD scholarship (2014-2015)
Perk Joep	Nothing to be declared (2014-2015)
Piepoli Massimo Francesco	Nothing to be declared (2014) A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Cardiovascular Prevention and Rehabilitation Initiatives (2015) - Novartis : Heart Failure Prevention Initiatives (2015) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : Heart Failure Prevention Initiatives (2015)
Prescott Eva	Nothing to be declared (2015) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Leo Pharma : Diverse (2014) - Novo Nordisk : Liraglutide (2014)
Redon Josep	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Diabetes (2014-2015) - Bristol Myers Squibb : Diabetes (2014-2015) - Boehringer-Ingelheim : Hypertension (2014-2015)

## 2016 European Guidelines on CVD prevention in clinical practice - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Redon Josep	<ul style="list-style-type: none"> <li>- Menarini : Hypertension (2014-2015)</li> <li>- MSD : Hypertension (2014-2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Hypertension (2014-2015)</li> </ul>
Richter Dimitrios	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Menarini : CAD- hypertension (2014-2015)</li> <li>- Novartis : hypertension (2014-2015)</li> <li>- Abbott : lipids (2014-2015)</li> <li>- Amgen : lipids (2014-2015)</li> <li>- Sanofi Aventis : Lipids (2014-2015)</li> <li>- Lilly : Lipids (2014-2015)</li> <li>- Unilever : lipids (2014-2015)</li> <li>- Merck Sharp &amp; Dohme : lipids (2014-2015)</li> <li>- Angelini : Lipids (2014-2015)</li> <li>- Vianex : lipids (2014-2015)</li> <li>- Galenica : Lipids (2014-2015)</li> <li>- Swisspharma : lipids-hypertension (2014-2015)</li> <li>- Astra Zeneca : lipids-thrombosis (2014-2015)</li> <li>- Pfizer : lipids-thrombosis (2014-2015)</li> <li>- Winmedica : lipids-thrombosis (2014-2015)</li> <li>- Boehringer-Ingelheim : thrombosis (2014-2015)</li> <li>- Bayer Healthcare : Thrombosis (2014-2015)</li> <li>- Teva Pharmaceutical Industries : lipids, hypertension (2015)</li> </ul>

## 2016 European Guidelines on CVD prevention in clinical practice - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Sattar Naveed	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : diabetes products (2014)</li> <li>- Eli Lilly : CETP inhibitor (2014-2015)</li> <li>- Amgen : PCSK9 (2014-2015)</li> <li>- Sanofi Aventis : PCSK9 (2014-2015)</li> <li>- Janssen-Cilag : Diabetes educational talk - not product related (2015)</li> <li>- Merck Sharp &amp; Dohme : Lipid-lowering (2015)</li> <li>- Boehringer-Ingelheim : SGLT2 inhibitor (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : GLP-1 trial (2014-2015)</li> <li>- Hoffman La Roche : IL-6R tocilizumab (2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Roche Pharma : biomarker research (2014-2015)</li> </ul>
Smulders Yvo	Nothing to be declared (2014-2015)
Tiberi Monica	Nothing to be declared (2014-2015)
van der Worp Bart	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer Netherlands : DOAC (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : oral anticoagulants; thrombolytic drugs (2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Bard : Therapeutic hypothermia (2014)</li> </ul>
Van Dis Ineke	Nothing to be declared (2014-2015)
Verschuren Monique	Nothing to be declared (2014-2015)

## Guidelines on CVD Prevention 2016 (TF14) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Aboyans Victor	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Antithrombotics (2014) - Sanofi Aventis : Hyperlipidemia (2014-2015) - Novartis : Hypertension (2014-2015) - Boehringer-Ingelheim : Oral anticoagulation (2014-2015) - Bayer Healthcare : Oral anticoagulation (2014-2015) - Pfizer/BMS alliance : Oral anticoagulation (2014-2015)
Andersen Karl	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : investigator, hypertension, heart failure, cor art disease (2014-2015)
Attia Ihab	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : Hypertension (2014) - Servier : Hypertension (2014) - Boehringer ingelhiem : Hypertension (2014) - Merck Sharp & Dohme : Lipid lowering therapy (2014) - Bayer AG : Rivaroxaban (2014) - Astra Zeneca : Ticagrelor (2014) Declaration not submitted (2015)
Bachl Norbert	Nothing to be declared (2014-2015)
Cho Leslie	Nothing to be declared (2014-2015)
Colkesen Ersen	Nothing to be declared (2014-2015)
Cox John	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Investigator - empagliflozin - SGLT2 inhibitor for type 2 diabetes (2014-2015)
Davletov Kairat	Nothing to be declared (2014-2015)
De Backer Guy	Nothing to be declared (2014)



## Guidelines on CVD Prevention 2016 (TF14) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
De Backer Guy	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Amgen : Lipid lowering drugs (2015) - Sanofi Aventis : Lipid lowering drugs (2015)
De Maeyer Catherine	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Daiichi Sankyo : Hypertension (2014-2015) - Sanofi Aventis : Hypercholesterolemia (2015)
De Sutter Johan	Nothing to be declared (2014)  D - Research funding (departmental or institutional). - Medtronic : heart failure (2015) - Novartis : heart failure (2015)
Delagardelle Charles	Nothing to be declared (2014-2015)
Dilic Mirza	Nothing to be declared (2014-2015)
Duishvili Davit	Nothing to be declared (2014-2015)
Egidi Guenther	Nothing to be declared (2014-2015)
Ferrieres Jean	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Sanofi Aventis : alirocumab (2014-2015) - Amgen : evolocumab (2014-2015)  - Merck Sharp & Dohme : ezetimibe (2014-2015) - Cerenis therapeutics : Atherosclerosis (2015)  D - Research funding (departmental or institutional). - Amgen : none (2014) - Medispec Limited : none (2014)
Filipova Slavomira	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer Healthcare : investigator - multicentric trial (2014) - Amgen Inc : investigator - multicentric trial, national investigator, International Steering Committee (2014)  - Servier : investigator - multicentric trial, speaker fees (2014)

## Guidelines on CVD Prevention 2016 (TF14) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Filipova Slavomira	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : investigator - multicentric trial (2014)</li> <li>- Amgen Inc : investigator - multicentric trial, national investigator (2014)</li> </ul> <p>Declaration not submitted (2015)</p>
Fisher Miles	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- GlaxoSmithKline : albiglutide (2014-2015)</li> <li>- Astra Zeneca : all diabetes products (2014-2015)</li> <li>- Janssen-Cilag : canagliflozin (2014-2015)</li> <li>- Sanofi Aventis : glagine, lixisenatide (2014-2015)</li> <li>- Boehringer Ingelheim / Eli Lilly : linagliptin, empagliflozin, dulaglutide, glargine (2014-2015)</li> <li>- Novo Nordisk : liraglutide, degludec (2014-2015)</li> <li>- MSD : sitagliptin (2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Janssen-Cilag : canagliflozin (2014-2015)</li> </ul>
Fitzsimons Donna	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Amgen : FH Treatment options (2014)</li> <li>- Amgen : lipid management (2015)</li> </ul>
Franco Duran Oscar	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Metagenics : Nutrition and genetics (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Nestle : Nutrition (2015)</li> <li>- Metagenics : Nutrition and genetics (2015)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- Metagenics : Lifestyle (2014)</li> <li>- Nestle : Nutrition (2014)</li> </ul>
Gale Christopher Peter	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Acute Coronary Syndrome (2014)</li> </ul>

## Guidelines on CVD Prevention 2016 (TF14) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Gale Christopher Peter	<ul style="list-style-type: none"> <li>- Novartis : Anti VEGF therapy (2014)</li> <li>- Astra Zeneca : Ticagrelor (2015)</li> </ul>
Gherasim Daniel	Nothing to be declared (2014-2015)
Giga Vojislav	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Cardio3 Biosciences : Stem cells in HF (2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Ministry of Science and Education of the Republic of Serbia : Educational grant (2014-2015)</li> </ul>
Gruev Ivan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Berlin Chemie AG : hypertension (2014)</li> <li>- Pfizer : hypertension, dyslipidemia (2014)</li> <li>- Actavis : hypertension, dyslipidemia (2014)</li> <li>- Servier : hypertension (2014-2015)</li> <li>- Egis Pharma : hypertension (2014-2015)</li> <li>- Novartis : herat failure (2015)</li> <li>- Sanofi Aventis : ischemic heart disease (2015)</li> <li>- Bayer : rivaroxaban (2015)</li> </ul>
Guenoun Maxime	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : cardiology (2014-2015)</li> <li>- Boehringer-Ingelheim : cardiology (2014-2015)</li> <li>- Pfizer : cardiology (2014-2015)</li> <li>- Servier : cardiology (2014-2015)</li> <li>- Meda pharma : cardiology (2014-2015)</li> <li>- Bayer Healthcare : cardiology (2014-2015)</li> <li>- Bristol Myers Squibb : cardiology (2014-2015)</li> </ul>

## Guidelines on CVD Prevention 2016 (TF14) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Guenoun Maxime	<ul style="list-style-type: none"> <li>- Medtronic : pacing (2014-2015)</li> <li>- Sorin Group : pacing (2014-2015)</li> </ul>
Gustafsson Ida	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : speaker fee (diabetes and CV disease) (2014-2015)</li> <li>- Boehringer-Ingelheim : Single advisory board meeting (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- GlaxoSmithKline : co-investigator in trial of albiglutide (2014-2015)</li> <li>- Novartis : co-investigator in trial of aliskeren (2014-2015)</li> <li>- Novartis : investigator in trial of LCZ696 (heart failure) (2014-2015)</li> <li>- Astra Zeneca : investigator in trial of ticagrelor (2014-2015)</li> </ul>
Hambrecht Rainer	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : eliquis (2014)</li> <li>- Lilly : prasugrel (2014-2015)</li> <li>- Berlin Chemie AG : ranolazin (2014-2015)</li> <li>- Astra Zeneca : ticagrelor (2014-2015)</li> <li>- Merck Sharp &amp; Dohme : tredaptive (2014-2015)</li> <li>- The Medicine Company : bivalirudine (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Medicines Company : Bivalirudin (2014-2015)</li> </ul>
Jankowski Piotr	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Antithrombotic drugs (2014)</li> <li>- Adamed : Cardiology (2014)</li> <li>- Astra Zeneca : Cardiology (2014)</li> <li>- Polpharma : Cardiology (2014)</li> <li>- Sanofi Aventis : Cardiology (2014)</li> </ul>

## Guidelines on CVD Prevention 2016 (TF14) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Jankowski Piotr	<ul style="list-style-type: none"> <li>- Krka Pharma : Cardiology (2014)</li> <li>- Sandoz : Hypertension (2014)</li> <li>- Amgen : Hypercholesterolemia (2014-2015)</li> <li>- Servier : Hypertension (2014-2015)</li> <li>- Boehringer-Ingelheim : Atrial fibrillation (2015)</li> <li>- Sanofi Aventis : Hypercholesterolemia (2015)</li> </ul>
Jashari Fisnik	Nothing to be declared (2014-2015)
Jennings Catriona Sian	Nothing to be declared (2014-2015)
Jug Borut	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Pfizer : Heart failure (2014)</li> <li>- Amgen : Dyslipidemia management (2014-2015)</li> <li>- Abbott Laboratories : Dyslipidemia management (2014-2015)</li> <li>- Krka Pharma : Dyslipidemia management &amp; heart failure (2014-2015)</li> <li>- Novartis : Heart failure (2014-2015)</li> <li>- Servier : Heart failure (2014-2015)</li> <li>- Astra Zeneca : CVD prevention (2015)</li> </ul>
Kerimkulova Alina	Nothing to be declared (2014-2015)
Kiessling Anna	<p>Nothing to be declared (2015)</p> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Stockholm County Council : Medical education research, not related to a specific product or therapeutic area (2014)</li> </ul>
Klimiashvili Zurab	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Hypertension (2014-2015)</li> </ul>
Kostova Nela	Nothing to be declared (2014-2015)
Kotseva Kornelia	Nothing to be declared (2014)

## Guidelines on CVD Prevention 2016 (TF14) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Kotseva Kornelia	D - Research funding (departmental or institutional). - European Society of Cardiology : Research grants from the ESC to IC London for the EUROASPIRE IV and V surveys (2015)
Mach Francois	Nothing to be declared (2014)  A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : Heart Failure (2015) - Menarini : Hypertension (2015) - Amgen : Lipid lowering (2015) - Sanofi Aventis : Lipid lowering (2015) - Merck Sharp & Dohme : Lipid lowering (2015) - Astra Zeneca : Lipid lowering, Hypertension, Heart Failure (2015) - Daiichi Sankyo : Lipid lowering, NOAC (2015) - Pfizer : Lipid lowering, NOAC (2015) - Bayer : NOAC (2015) - Boehringer-Ingelheim : NOAC (2015) - Bristol Myers Squibb : NOAC (2015)  D - Research funding (departmental or institutional). - Amgen : Lipid lowering (2015) - Merck Sharp & Dohme : Lipid lowering (2015)
Magri Caroline Jane	Nothing to be declared (2014-2015)
Mahdhaoui Abdallah	Nothing to be declared (2014-2015)
Mancia Giuseppe	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Medtronic : cardiovascular area (2014) - Servier : cardiovascular area (2014) - Ferrer Internacional : cardiovascular area (2014)

## Guidelines on CVD Prevention 2016 (TF14) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Mancia Giuseppe	<ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : cardiovascular area (2014)</li> <li>- Recordati International : cardiovascular area (2014)</li> <li>- Boehringer Ingelheim : cardiovascular area (2014)</li> <li>- Novartis Pharma : cardiovascular area (2014)</li> <li>- Bayer AG : Antihypertensive Treatment (2015)</li> <li>- Merck Sharp &amp; Dohme : Antihypertensive Treatment (2015)</li> <li>- Boehringer-Ingelheim : Antihypertensive Treatment (2015)</li> <li>- Covidien : Antihypertensive Treatment (2015)</li> <li>- Daiichi Sankyo : Antihypertensive Treatment (2015)</li> <li>- Novartis : Antihypertensive Treatment (2015)</li> <li>- Menarini : Antihypertensive Treatment (2015)</li> <li>- Actavis : Antihypertensive Treatment (2015)</li> <li>- Medtronic Foundation : Antihypertensive Treatment (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Antihypertensive Treatment (2015)</li> <li>- Sanofi Aventis : Antihypertensive Treatment (2015)</li> <li>- Recordati International : Antihypertensive Treatment (2015)</li> </ul>
Martin Franz	<p>Nothing to be declared (2014)</p> <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> <li>- Biomedal SL : Celiac Disease (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Spanish Ministry of Science : Type 2 Diabetes and NAFLD (2015)</li> </ul>
Metzler Bernhard	Nothing to be declared (2014-2015)
Mezzani Alessandro	Nothing to be declared (2014-2015)

## Guidelines on CVD Prevention 2016 (TF14) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Milicic Davor	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : cardiovascular drugs (2014)</li> <li>- Boehringer-Ingelheim : cardiovascular drugs (2014)</li> <li>- Pfizer : cardiovascular drugs (2014)</li> <li>- Sanofi Aventis : cardiovascular drugs (2014)</li> <li>- Bayer Healthcare : cardiovascular drugs (2014)</li> <li>- Krka Pharma : cardiovascular drugs (2014)</li> <li>- Pliva, : cardiovascular drugs (2014)</li> <li>- Thoratec : mechanical circulatory support (2014)</li> <li>- Marck Medical : mechanical circulatory support (2014)</li> <li>- Roche Diagnostics : Biomarkers (2015)</li> <li>- Heartware : LVAD (2015)</li> <li>- Boehringer-Ingelheim : NOACS (2015)</li> <li>- Bayer Healthcare : NOACS (2015)</li> <li>- Amgen : PCSK9 inhibitors (2015)</li> <li>- Astra Zeneca : Ticagrelor (2015)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- University of Zagreb : Platelet reactivity to antithrombotic drugs (2014)</li> </ul>
Mintale Iveta	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : speaker fees (2014-2015)</li> <li>- Servier : speaker fees (2014-2015)</li> <li>- Berlin Chemie AG : speaker fees (2014-2015)</li> <li>- Merck Serono : speaker fees (2014-2015)</li> </ul>
Najafov Ruslan	Nothing to be declared (2014-2015)



## Guidelines on CVD Prevention 2016 (TF14) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Nedogoda Sergey	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott : Arterial hypertension (2014-2015)</li> <li>- Servier : Arterial hypertension (2014-2015)</li> <li>- Takeda Pharmaceuticals : Diabetes (2014-2015)</li> <li>- Astra Zeneca : Diabetes, pulmo (2014-2015)</li> <li>- Boehringer-Ingelheim : Pulmo (2014-2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Arterial Hypertension (2014-2015)</li> <li>- Astra Zeneca : Diabetes, pulmo (2014-2015)</li> <li>- Boehringer-Ingelheim : Pulmo (2014-2015)</li> </ul>
Nesukay Elena	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : cardiology (2014-2015)</li> </ul>
Niessner Alexander	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : anticoagulation (2014-2015)</li> <li>- Boehringer-Ingelheim : anticoagulation (2014-2015)</li> <li>- Daiichi Sankyo : anticoagulation (2014-2015)</li> <li>- Pfizer : anticoagulation (2014-2015)</li> <li>- Bristol Myers Squibb : anticoagulation (2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : atrial fibrillation (2014-2015)</li> </ul>
Novo Salvatore	<p>Nothing to be declared (2015)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- MSD : Statins (2014)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Apixaban (2014)</li> </ul>
Oukerraj Latifa	<p>Nothing to be declared (2014-2015)</p>

## Guidelines on CVD Prevention 2016 (TF14) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Palma Dos Reis Roberto Jose	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - Meda pharma : Several products, main OTCs. Some cardiovascular drugs (2014-2015)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - Merck Sharp &amp; Dohme : I have participated in Improve it (Clinical trial), as Primary Investigator (2014)</p>
Petrulioniene Zaneta	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Arterial hypertension (2014)</li> <li>- Novartis : Arterial hypertension (2014)</li> <li>- Krka Pharma : Dyslipidaemia (2014)</li> <li>- Grindex : Heart failure (2014)</li> <li>- Pfizer : Dyslipidaemia (2015)</li> <li>- Sanofi Aventis : Dyslipidaemia (2015)</li> <li>- Novartis : Heart failure (2015)</li> </ul>
Ponikowski Piotr	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : acute coronary syndrome (2014)</li> <li>- Boehringer-Ingelheim : anticoagulant (2014)</li> <li>- Respicardia : anticoagulant (2014)</li> <li>- Johnson &amp; Johnson : heart failure (2014)</li> <li>- Pfizer : heart failure, anticoagulant (2014)</li> <li>- MSD : lipids (2014)</li> <li>- Abbott Vascular : devices (2014-2015)</li> <li>- Novartis : heart failure (2014-2015)</li> <li>- Cardiorentis : heart failure (2014-2015)</li> <li>- Bayer Healthcare : heart failure (2014-2015)</li> <li>- Vifor Pharma ltd : heart failure (2014-2015)</li> </ul>

## Guidelines on CVD Prevention 2016 (TF14) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Ponikowski Piotr	<ul style="list-style-type: none"> <li>- CIBIEM : heart failure (2014-2015)</li> <li>- Servier : heart failure, coronary artery disease (2014-2015)</li> <li>- Amgen : heart failure, lipids (2014-2015)</li> <li>- Boehringer-Ingelheim : anticoagulant, diabetes (2015)</li> <li>- Respocardia : devices (2015)</li> <li>- BioControl : devices (2015)</li> <li>- DC Device : devices (2015)</li> <li>- Celladon : heart failure (2015)</li> <li>- Pfizer : lipids (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : acute coronary syndrome (2014)</li> <li>- Vifor Pharma ltd : heart failure (2014)</li> <li>- MSD : lipids (2014)</li> <li>- Respocardia : anticoagulant (2014-2015)</li> <li>- Novartis : heart failure (2014-2015)</li> <li>- Cardioentis : heart failure (2014-2015)</li> <li>- Bayer Healthcare : heart failure (2014-2015)</li> <li>- CIBIEM : heart failure (2014-2015)</li> <li>- Servier : heart failure, coronary artery disease (2014-2015)</li> <li>- Amgen : heart failure, lipids (2014-2015)</li> <li>- BioControl : devices (2015)</li> <li>- DC Device : devices (2015)</li> <li>- Celladon : heart failure (2015)</li> </ul>

## Guidelines on CVD Prevention 2016 (TF14) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Rauch Bernhard	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : cryoablation (2014)</li> <li>- Novartis : clinical trial on drug therapy (2015)</li> <li>- Abbott : coronary stents (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Pfizer : meta-analysis on the prognostic outcome of cardiac rehabilitation (2014)</li> <li>- Deutsche Herzstiftung : meta-analysis on the prognostic outcome of cardiac rehabilitation (2014)</li> <li>- Deutsche Gesellschaft für Prävention und Rehabilitation von Herz-Kreislaufkrankungen, e.V. , DGPR : meta-analysis on the prognostic outcome of cardiac rehabilitation (2014)</li> <li>- Pfizer : cardiac rehabilitation (2015)</li> <li>- Deutsche Herzstiftung : cardiac rehabilitation (2015)</li> <li>- German Society of Cardiovascular Prevention and Rehabilitation : cardiac rehabilitation (2015)</li> </ul>
Rodriguez Padiá Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Atrial fibrillation (2014-2015)</li> <li>- Pfizer : Atrial fibrillation (2014-2015)</li> <li>- Astra Zeneca : CAD (2014-2015)</li> <li>- Servier : CHF (2014-2015)</li> <li>- Rovi : Ivabradine (2014-2015)</li> <li>- Merck Sharp &amp; Dohme : Lipids (2014-2015)</li> <li>- Lacer : diltiazem (2015)</li> <li>- Daiichi Sankyo : Hypertension (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Atrial fibrillation (2014-2015)</li> <li>- Bayer : Atrial fibrillation (2015)</li> </ul>
Roffi Marco	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Johnson &amp; Johnson : coronary catheters (2014-2015)</li> </ul>

## Guidelines on CVD Prevention 2016 (TF14) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Roffi Marco	<ul style="list-style-type: none"> <li>- Astra Zeneca : speaker fees related to the 2015 ESC NSTEMI GL (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Biosensors : devices (2014-2015)</li> <li>- Boston Scientific : devices (2014-2015)</li> <li>- Medtronic : devices (2014-2015)</li> <li>- Biotronik : devices (2014-2015)</li> <li>- Abbott Vascular : devices (2014-2015)</li> <li>- Terumo Inc : devices (2015)</li> </ul>
Rudi Victor	Nothing to be declared (2014-2015)
Ryden Lars	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Diabetes and cardiovascular disease. Advisory committee fee (2014)</li> <li>- Sanofi Aventis : Advisory Board and lectures (2014-2015)</li> <li>- Merck Sharp &amp; Dohme : Cardiology; Course organisation, lecture (2014-2015)</li> <li>- Boehringer Ingelheim Pharma GmbH &amp; Co. KG : Diabetes and cardiovascular disease. Expert committee work. (2014-2015)</li> <li>- Astra Zeneca : Diabetes and cardiovascular disease; Advisory Board and occasional lecture fees (2014-2015)</li> <li>- Bayer : Diabetes and cardiovascular disease; Lecture fees (2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Bayer : Pharma (2015)</li> <li>- Boehringer Ingelheim : Pharma (2015)</li> <li>- Novo-Nordic : Pharma (2015)</li> </ul>
Saade Georges	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Merck Serono : Speaker Fee (2014)</li> <li>- Boehringer-Ingelheim : Speaker fees (2014)</li> <li>- Bayer, : NOAC (2015)</li> </ul>

## Guidelines on CVD Prevention 2016 (TF14) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Saade Georges	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : Committee Member (2014)</p> <p>D - Research funding (departmental or institutional). - Sanofi Aventis : LMWH (2015)</p> <p>E - Research funding (personal). - Pfizer : Research (2014)</p>
Schirmer Henrik	<p>Nothing to be declared (2014)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Merck Sharp &amp; Dohme : Cholesterol lowering ezetemib (2015)</p>
Stauder Adrienne	<p>Nothing to be declared (2014)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Teva Pharmaceutical Industries : Parkinsons Disease / speakers fee (2015)</p>
Stelmashok Valeriy	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Medtronic Foundation : I took part on Medtronic Advisory Board Meeting (2014) - Medtronic : advisory board team member (2015)</p>
Szabados Eszter	<p>Nothing to be declared (2014-2015)</p>
Tsioufis Costas	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Honoraria, Travel Expenses (2014-2015)</li> <li>- Bayer : Honoraria, Travel Expenses (2014-2015)</li> <li>- Boehringer-Ingelheim : Honoraria, Travel Expenses (2014-2015)</li> <li>- Medtronic : Honoraria, Travel Expenses (2014-2015)</li> <li>- Novartis : Honoraria, Travel Expenses (2014-2015)</li> <li>- Pfizer : Honoraria, Travel Expenses (2014-2015)</li> <li>- St Jude Medical : Honoraria, Travel Expenses (2014-2015)</li> <li>- Sanofi Aventis : Honoraria, Travel Expenses (2014-2015)</li> <li>- Menarini : Honoraria, Travel Expenses (2014-2015)</li> </ul>

## Guidelines on CVD Prevention 2016 (TF14) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Tsioufis Costas	D - Research funding (departmental or institutional). - Recordati International : Funding (2014-2015) - St Jude Medical : Renal denervation (2014-2015)
Turc Guillaume	Nothing to be declared (2014-2015)
Ural Dilek	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pfizer : Apixabane (2014) - Novartis : Heart failure (investigator in clinical trials and member of local advisory board) (2014) - Novartis : Amlodipin-valsartan combination (2015) - Pfizer : Apixaban (2015) - Merck Sharp & Dohme : Ezetimibe (2015) - Novartis : LCZ696 (2015)
Vaughan Carl	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : pharmacologic therapy (2014) - Astra Zeneca, Novartis : pharmacologic therapy (2015)
Vaverkova Helena	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Sanofi Aventis : alirocumab - consultancy (2014) - Amgen s.r.o. Praha : evolocumab - advisory board (2014-2015) - Merc Sharp and Dohme s.r.o. Praha : ezetimibe - advisory board (2014-2015) - AOP OrOrphan Pharmaceuticals AG, Praha : lomitapide - consultancy (2014-2015) - Sanofi Aventis : alirocumab - congress (2015)
Wiklund Olov	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Sanofi Aventis : cardiovascular prevention (2014) - Astra Zeneca : Cardiovascular prevention (2014-2015) - Boehringer-Ingelheim : Cardiovascular prevention (2014-2015) - Amgen Inc : cardiovascular prevention (2014-2015)

## Guidelines on CVD Prevention 2016 (TF14) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Wiklund Olov	<ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : cardiovascular prevention (2014-2015)</li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Quintiles : Diabetes (2014)</li> <li>- Astra Zeneca : Basic cardiovascular (2014-2015)</li> <li>- DuPont : Cardiovascular (2014-2015)</li> <li>- Cebix inc : Diabetes (2014-2015)</li> <li>- Sanof-Aventis : Cartdiovascular (2015)</li> </ul> </li> </ul>
Zafirir Barak	Nothing to be declared (2014-2015)
Zamorano Gomez Jose Luis	<ul style="list-style-type: none"> <li>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.               <ul style="list-style-type: none"> <li>- Philips : 3D echo (2014)</li> <li>- Toshiba medical imaging : fusion imaging 3D echo CT (2014)</li> <li>- Astra Zeneca : Speaker fee for 1 talk in 2014 (2014)</li> <li>- MSD : CV risk factors (2014-2015)</li> <li>- Abbott : Lecturing (2015)</li> <li>- Pfizer : Lecturing (2015)</li> <li>- Sorin Group : Respicardia echo protocol (2015)</li> </ul> </li> <li>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.               <ul style="list-style-type: none"> <li>- Siemens Healthcare : 3d echo software and free style echo (2014-2015)</li> <li>- Toshiba medical imaging : Fusion Imaging (2015)</li> </ul> </li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Amgen : Clinical trial (2014-2015)</li> <li>- Novartis : Clinical trial (2014-2015)</li> <li>- Ikaria : Clinical trial (2014-2015)</li> </ul> </li> </ul>



## Guidelines on CVD Prevention 2016 (TF14) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Zavatta Marco	Nothing to be declared (2014-2015)

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Aboyans Victor	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antithrombotics (2014)</li> <li>- Sanofi Aventis : Hyperlipidemia (2014-2015)</li> <li>- Novartis : Hypertension (2014-2015)</li> <li>- Boehringer-Ingelheim : Oral anticoagulation (2014-2015)</li> <li>- Bayer Healthcare : Oral anticoagulation (2014-2015)</li> <li>- Pfizer/BMS alliance : Oral anticoagulation (2014-2015)</li> </ul>
Achenbach Stephan	<p>Nothing to be declared (2015)</p> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Abbott : Coronary Intervention (2014)</li> </ul>
Agewall Stefan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Thermo Fischer Scientific : Cardiac markers (2014-2015)</li> <li>- Astra Zeneca : Platelet inhibition (2014-2015)</li> <li>- Vifor International : Heart failure (2015)</li> </ul>
Badimon Lina	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- MSD-España : Lipids (2014)</li> <li>- Sanofi Aventis : lipids (2014-2015)</li> <li>- Burson Masteller : nutrition (2014-2015)</li> <li>- Astra Zeneca : thrombosis (2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Astrazeneca : thrombosis (2014-2015)</li> </ul>
Baron Esquivias Gonzalo	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulation (2014)</li> <li>- Boehringer-Ingelheim : Anticoagulation (2014-2015)</li> <li>- Daiichi Sankyo : Anticoagulation (2014-2015)</li> <li>- Pfizer : Anticoagulation (2014-2015)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Baron Esquivias Gonzalo	<ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : Dyslipemia (2015)</li> </ul>
Baumgartner Helmut	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Actelion : Bosentan and Macicentan for PAH treatment in congenital heart disease (2014-2015)</li> <li>- St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2014-2015)</li> <li>- Abbott : transcather mitral valve repair (Mitraclip) (2014-2015)</li> <li>- Edwards Lifesciences : transcatheter valve implantation (2014-2015)</li> <li>- Direct Flow Medical : transcatheter valve implantation (2014-2015)</li> <li>- Gore : Occluders for shunt closure (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Actelion : Bosentan for PAH treatment in congenital heart disease (2014-2015)</li> <li>- St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2014-2015)</li> <li>- Abbott : transcather mitral valve repair (Mitraclip) (2014-2015)</li> <li>- Edwards Lifesciences : transcatheter valve implantation (2014-2015)</li> <li>- Direct Flow Medical : transcatheter valve implantation (2014-2015)</li> <li>- Gore : Occluders for shunt closure (2015)</li> </ul>
Bax Jeroen	Nothing to be declared (2014-2015)
Bueno Hector	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Aspirin, rivaroxaban (2014)</li> <li>- Menarini : Ranolazine (2014)</li> <li>- Novartis : Serelaxin (2014)</li> <li>- Pfizer : Apixaban (2014-2015)</li> <li>- Bristol Myers Squibb : Apixaban (2014-2015)</li> <li>- Sanofi Aventis : Clopidogrel (2014-2015)</li> <li>- Servier : ivabradine (2014-2015)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Bueno Hector	<ul style="list-style-type: none"> <li>- Daiichi Sankyo : Prasugrel (2014-2015)</li> <li>- Eli Lilly : Prasugrel (2014-2015)</li> <li>- Astra Zeneca : Ticagrelor (2014-2015)</li> <li>- Bayer Healthcare : Aspirin (2015)</li> <li>- Novartis : Serelaxin, LCZ696 (2015)</li> <li>- Ferrer Internacional : Trinomia (polypill) (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Ticagrelor (2015)</p> <p>E - Research funding (personal). - Astra Zeneca : Ticagrelor (2014-2015)</p>
Carerj Scipione	Nothing to be declared (2014-2015)
Erol Cetin	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Hypertension (2014-2015)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Menarini : Hypertension (2014-2015)</p>
Fitzsimons Donna	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Amgen : FH Treatment options (2014) - Amgen : lipid management (2015)</p>
Gaemperli Oliver	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Biosensors : Stents (2014) - Abbott Vascular : MitraClip (2015) - Biosensors : Travel Grant to AsiaPCR 2015 (2015)</p>
Kirchhof Paulus	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Daiichi Sankyo : cardiovascular (2014) - Pfizer : cardiovascular (2014) - Bristol Myers Squibb : cardiovascular (2014)</p>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Kirchhof Paulus	<ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : cardiovascular (2014-2015)</li> <li>- Medtronic : cardiovascular (2014-2015)</li> <li>- St Jude Medical : cardiovascular (2014-2015)</li> <li>- Sanofi Aventis : cardiovascular (2014-2015)</li> <li>- Meda pharma : cardiovascular (2014-2015)</li> <li>- Merck Sharp &amp; Dohme : cardiovascular (2014-2015)</li> <li>- Medscape : cardiovascular (2014-2015)</li> <li>- Astra Zeneca : cardiovascular (2015)</li> <li>- Servier : cardiovascular (2015)</li> <li>- Bayer Healthcare : cardiovascular (2015)</li> <li>- Bayer Vital : cardiovascular (2015)</li> <li>- Correvio : cardiovascular (2015)</li> <li>- Daiichi Sankyo Europe : cardiovascular (2015)</li> <li>- Bristol Myers Squibb Global : cardiovascular (2015)</li> <li>- Pfizer Global : cardiovascular (2015)</li> <li>- Pfizer Germany : cardiovascular (2015)</li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Daiichi Sankyo : cardiovascular (2014-2015)</li> <li>- St Jude Medical : cardiovascular (2014-2015)</li> <li>- Sanofi Aventis : cardiovascular (2014-2015)</li> <li>- Meda pharma : cardiovascular (2014-2015)</li> <li>- British Heart Foundation : cardiovascular (2014-2015)</li> <li>- BMS / Pfizer alliance : cardiovascular (2014-2015)</li> </ul> </li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Kirchhof Paulus	<ul style="list-style-type: none"> <li>- Leducq Foundation : cardiovascular (2014-2015)</li> <li>- European Union FP7 : cardiovascular (2014-2015)</li> <li>- European Union horizon2020 : cardiovascular (2014-2015)</li> <li>- German Centre for Heart Research (DZHK, funded by German Ministry of Education and Research) : cardiovascular (2014-2015)</li> <li>- UK Medical Research Council : cardiovascular (2015)</li> </ul>
Kolh Philippe H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antiplatelet agents (2014-2015)</li> <li>- B.Braun : Surgical instruments (2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : Cardiac valves (2014-2015)</li> <li>- Medtronic : Cardiac valves (2014-2015)</li> </ul>
Lancellotti Patrizio	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Menarini : nebivolol (2014)</li> <li>- St Jude Medical : Echo course (2015)</li> <li>- Servier : Imaging Ischemic disease (2015)</li> <li>- Boston Scientific : Sudden death (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : CRT (2014)</li> <li>- Servier : procoralan (2014)</li> <li>- Bayer : NOAC (2015)</li> </ul>
Lip Gregory Y H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : atrial fibrillation (2014-2015)</li> <li>- Biotronik : atrial fibrillation (2014-2015)</li> <li>- Boehringer-Ingelheim : atrial fibrillation, thrombosis (2014-2015)</li> <li>- Daiichi Sankyo : atrial fibrillation, thrombosis (2014-2015)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Lip Gregory Y H	<ul style="list-style-type: none"> <li>- Pfizer : atrial fibrillation, thrombosis (2014-2015)</li> <li>- Bayer Healthcare : atrial fibrillation, thrombosis (2014-2015)</li> <li>- Bristol Myers Squibb : atrial fibrillation, thrombosis (2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : atrial fibrillation, thrombosis (2014-2015)</li> </ul>
Nihoyannopoulos Petros	Nothing to be declared (2014-2015)
Piepoli Massimo Francesco	<p>Nothing to be declared (2014)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Cardiovascular Prevention and Rehabilitation Initiatives (2015)</li> <li>- Novartis : Heart Failure Prevention Initiatives (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : Heart Failure Prevention Initiatives (2015)</li> </ul>
Ponikowski Piotr	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : acute coronary syndrome (2014)</li> <li>- Boehringer-Ingelheim : anticoagulant (2014)</li> <li>- Respicardia : anticoagulant (2014)</li> <li>- Johnson &amp; Johnson : heart failure (2014)</li> <li>- Pfizer : heart failure, anticoagulant (2014)</li> <li>- MSD : lipids (2014)</li> <li>- Abbott Vascular : devices (2014-2015)</li> <li>- Novartis : heart failure (2014-2015)</li> <li>- Cardiorentis : heart failure (2014-2015)</li> <li>- Bayer Healthcare : heart failure (2014-2015)</li> <li>- Vifor Pharma ltd : heart failure (2014-2015)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Ponikowski Piotr	<ul style="list-style-type: none"> <li>- CIBIEM : heart failure (2014-2015)</li> <li>- Servier : heart failure, coronary artery disease (2014-2015)</li> <li>- Amgen : heart failure, lipids (2014-2015)</li> <li>- Boehringer-Ingelheim : anticoagulant, diabetes (2015)</li> <li>- Respicardia : devices (2015)</li> <li>- BioControl : devices (2015)</li> <li>- DC Device : devices (2015)</li> <li>- Celladon : heart failure (2015)</li> <li>- Pfizer : lipids (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : acute coronary syndrome (2014)</li> <li>- Vifor Pharma ltd : heart failure (2014)</li> <li>- MSD : lipids (2014)</li> <li>- Respicardia : anticoagulant (2014-2015)</li> <li>- Novartis : heart failure (2014-2015)</li> <li>- Cardioentis : heart failure (2014-2015)</li> <li>- Bayer Healthcare : heart failure (2014-2015)</li> <li>- CIBIEM : heart failure (2014-2015)</li> <li>- Servier : heart failure, coronary artery disease (2014-2015)</li> <li>- Amgen : heart failure, lipids (2014-2015)</li> <li>- BioControl : devices (2015)</li> <li>- DC Device : devices (2015)</li> <li>- Celladon : heart failure (2015)</li> </ul>



## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Roffi Marco	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Johnson &amp; Johnson : coronary catheters (2014-2015)</li> <li>- Astra Zeneca : speaker fees related to the 2015 ESC NSTEMI GL (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Biosensors : devices (2014-2015)</li> <li>- Boston Scientific : devices (2014-2015)</li> <li>- Medtronic : devices (2014-2015)</li> <li>- Biotronik : devices (2014-2015)</li> <li>- Abbott Vascular : devices (2014-2015)</li> <li>- Terumo Inc : devices (2015)</li> </ul>
Torbicki Adam	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Pulmonary arterial hypertension (2014)</li> <li>- GlaxoSmithKline : pulmonary arterial hypertension - ambrisentan (2014)</li> <li>- Lilly : pulmonary arterial hypertension - ambrisentan (2014)</li> <li>- Actelion : pulmonary arterial hypertension - macitentan, selexipag (2014-2015)</li> <li>- Bayer Healthcare : pulmonary arterial hypertension - iloprost, riociguat, VTE - xarelto (2014-2015)</li> <li>- Teva Pharmaceutical Industries : anti-cancer treatment (2015)</li> <li>- Sanofi Aventis : anticoagulants (2015)</li> <li>- AOP Orphan Pharmaceuticals : pulmonary arterial hypertension (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Pulmonary hypertension (2014-2015)</li> </ul>
Vaz Carneiro Antonio	<p>Nothing to be declared (2015)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- AbbVie : Oncology (2014)</li> </ul>
Windecker Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Eli Lilly : Antiplatelet therapy (2014)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> <li>- Bayer Healthcare : Antithrombotic drug (2014)</li> <li>- Abbott : Stent and Heartvalvetherapy (2014)</li> <li>- Biosensors : Stents (2014)</li> <li>- Boston Scientific : Stents (2014)</li> <li>- Astra Zeneca : Antiplatelet therapy (2014-2015)</li> <li>- Daiichi Sankyo : Antiplatelet therapy (2015)</li> <li>- Boston Scientific : Complex PCI (2015)</li> <li>- Sanofi Aventis : Managing Dyslipidemia (2015)</li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Medicines Company : Antithrombotic therapy (2014)</li> <li>- Johnson &amp; Johnson : Catheters (2014)</li> <li>- Edwards Lifesciences : Heartvalves (2014)</li> <li>- St Jude Medical : OCT (2014)</li> <li>- Abbott : Stent (2014)</li> <li>- Biotronik : Stent (2014)</li> <li>- Boston Scientific : Stent and Heartvalves (2014)</li> <li>- Medtronic : Stent and Heartvalves (2014)</li> <li>- Sorin Group : Electrophysiology (2015)</li> <li>- Biotronik : Electrophysiology (2015)</li> <li>- Johnson &amp; Johnson : Electrophysiology and PCI (2015)</li> <li>- Guerbet : Imaging (2015)</li> <li>- Novartis : IMP (2015)</li> <li>- Actelion : IMP (2015)</li> </ul> </li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> <li>- Medicines Company : IMP (2015)</li> <li>- Merck Sharp &amp; Dohme : IMP (2015)</li> <li>- St Jude Medical : PCI (2015)</li> <li>- Abbott : PCI and Structural Heart Disease (2015)</li> <li>- Boston Scientific : Structural Heart Disease (2015)</li> <li>- Edwards Lifesciences : Structural Heart Disease (2015)</li> <li>- Symetis SA : Structural Heart Disease (2015)</li> <li>- Medtronic : Structural Heat Disease (2015)</li> </ul>
Zamorano Gomez Jose Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Philips : 3D echo (2014)</li> <li>- Toshiba medical imaging : fusion imaging 3D echo CT (2014)</li> <li>- Astra Zeneca : Speaker fee for 1 talk in 2014 (2014)</li> <li>- MSD : CV risk factors (2014-2015)</li> <li>- Abbott : Lecturing (2015)</li> <li>- Pfizer : Lecturing (2015)</li> <li>- Sorin Group : Respicardia echo protocol (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Siemens Healthcare : 3d echo software and free style echo (2014-2015)</li> <li>- Toshiba medical imaging : Fusion Imaging (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Amgen : Clinical trial (2014-2015)</li> <li>- Novartis : Clinical trial (2014-2015)</li> <li>- Ikaria : Clinical trial (2014-2015)</li> </ul>